American Thoracic Society - Sanofi Investor Call slide image

American Thoracic Society - Sanofi Investor Call

sanofi Ambition to transform the practice of medicine in Respiratory 8 ATS Investor Call DUPIXENT (dupilumab) Lead Key Type 2 inflammatory diseases itepekimab amlitelimab rilzabrutinib SAR'765 Expand Breakthrough medicines beyond Type 2 Disrupt Transformative technologies
View entire presentation